Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-20

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urinary Tract Infections (UTIs) are among the most common bacterial infections. Although they are typically treated effectively with antibiotics, recurrence is a frequent and troublesome issue.

This clinical trial aims to evaluate the safety and effectiveness of Multi-Gyn UT Protect gel in preventing the recurrence of UTIs. The trial will involve 50 adult female participants who have experienced a UTI in recent months but do not currently have an active infection.

Each participant will apply the gel twice a week for four months. They will be monitored throughout this period to assess whether participants develop the reappearance of UTI symptoms.

The primary objective is to determine how many participants do not experience a recurrence of UTI by the end of the four-month treatment period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections

NCT07234786

Bacterial Vaginosis Vaginal Candidiasis

RECRUITING NA

Single Arm Study of Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis

NCT05211921

Bacterial Vaginosis

COMPLETED NA

Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)

NCT01437722

Recurrent Bacterial Vaginosis (BV)

COMPLETED PHASE2

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950

Bacterial Vaginosis

COMPLETED PHASE3

Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis

NCT04807842

Bacterial Vaginoses

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Tract Infections (UTIs)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Vaginal gel

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study product

Multi-Gyn UT Protect gel

Group Type EXPERIMENTAL

Multi-Gyn UT Protect gel

Intervention Type DEVICE

Vaginal gel

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multi-Gyn UT Protect gel

Vaginal gel

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 18 to 84 years old.
2. Sex: Female.
3. Subject suffering from uncomplicated recurrent urinary tract infections: ≥ 4. UTIs within 12 months or ≥ 2 within 6 months.
4. Subject having given freely and expressly her informed consent.
5. Subject using a contraceptive regimen recognized as effective (pill, implant, Intra Uterine Device (IUD), condoms) since at least 12 weeks before inclusion visit and during the whole study. If subject use condoms as contraceptive regimen, a delay of 6 hours between application and sexual intercourse must be respected.
6. Subject affiliated to a health social security system.
7. Subject cooperative and aware of the device's modalities of use and the necessity and duration of the follow-up visits so that perfect adhesion to the protocol can be expected.

Exclusion Criteria

1. Pregnant or nursing woman or planning a pregnancy during the study.
2. Subject who gave birth in the 3 previous months.
3. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
4. Subject in a social or sanitary establishment.
5. Subject suspected to be non-compliant according to the investigator's judgment.
6. Subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study.
7. Subject enrolled in another clinical trial or which exclusion period is not over.
8. Subject with history of complicated urinary tract infection.
9. Subject with urinary tract infection at the time of inclusion.
10. Subject with vaginal mycosis infection in the last 3 weeks.
11. Subject with recurrent vaginal mycosis (more than 2 in the last 6 months).
12. Subject having a known allergy or hypersensitivity to one of the components of the investigational device.
13. Subject suffering from a sexually transmitted gynaecological infection or aerobic vaginitis (including gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis, urethritis, salpingitis).
14. Subject with history of hormone-dependent cancer or bladder cancer.
15. Subject with current genital malignancies.
16. Subject who had a chemotherapy treatment for a cancer in the 12 months before inclusion.
17. Subject who had a radiotherapy treatment in the genito-urinary area in the 12 months before inclusion.
18. Subject using treatment for urinary tract infection, vaginal conditions, vaginal infections, or other intravaginal treatment at the time of inclusion.
19. Subject using food supplements for prevention of urinary tract infection in the last 3 months.
20. Subject using antibiotics, corticoids or antifungal treatment for any reason in the 3 weeks before inclusion.
21. Subject using vaginal douches and who do not wish to refrain using them during the clinical investigation.
22. Subject with a pessary.
23. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.

Minimum Eligible Age

18 Years

Maximum Eligible Age

84 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes